Sugi Predict

Sugi Predict / Compounds / SCHEMBL975740

SCHEMBL975740

SCHEMBL975740

NC(=S)C1CCN(C(=O)O)CC1

nearest known ligand 0.41

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 1/20 0.41
▸ CA1 P00915 1/20 0.41
▸ CA2 P00918 1/20 0.41
▸ CA9 Q16790 1/20 0.41
▸ SMN1; SMN2 Q16637 6/20 0.39
▸ GAA P10253 2/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ ALDH1A1 P00352 3/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.36
▸ PKM P14618 1/20 0.36
▸ LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15376451 0.88 SMN1; SMN2 (0.40) CA12CA1CA2CA9SMN1; SMN2
SCHEMBL2030080 0.82 GAA (0.55) SMN1; SMN2GAAALDH1A1KDM4ETDP1
SCHEMBL12036169 0.81 EPHX2 (0.42) CA12CA1CA2CA9SMN1; SMN2
SCHEMBL4537101 0.78 NOS2 (0.50) SMN1; SMN2GAAKDM4ETDP1LMNA
SCHEMBL16405708 0.78 SMN1; SMN2 (0.47) CA12CA1CA2CA9SMN1; SMN2
SCHEMBL2573409 0.77 ALDH1A1 (0.35) CA12CA1CA2CA9SMN1; SMN2
SCHEMBL587681 0.77 LMNA (0.53) SMN1; SMN2GAAALDH1A1KDM4ELMNA
SCHEMBL660702 0.76 ALDH1A1 (0.50) CA12CA1CA2CA9SMN1; SMN2
SCHEMBL2933002 0.75 LMNA (0.37) SMN1; SMN2GAAALDH1A1KDM4ETDP1
SCHEMBL2933003 0.75 LMNA (0.37) SMN1; SMN2GAAALDH1A1KDM4ETDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220411440-A1 GLYCOSIDASE INHIBITORS ASCENEURON SA (CH) 2022-12-29 — — US disclosed
EP-4065574-A1 SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION Bayer Aktiengesellschaft (DE) 2022-10-05 — — EP disclosed
CN-113248488-A Novel heterocyclic amide piperidine derivative, preparation method thereof and application thereof in hypoglycemic drugs 林剑雄 2021-08-13 — — CN disclosed
CN-113185509-A Compound containing indole ring structure, preparation method and application thereof, and bactericide 华中师范大学 2021-07-30 — — CN disclosed
EP-3186243-B1 GLYCOSIDASE INHIBITORS ASCENEURON SA (CH) 2021-07-21 — — EP disclosed
US-11046712-B2 Glycosidase inhibitors ASCENEURON SA (CH) 2021-06-29 — — US disclosed
WO-2021105117-A1 SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2021-06-03 — — WO disclosed
CN-112812110-A Novel benzo heterocyclic ether derivative, preparation method thereof and application thereof in hypoglycemic drugs 林剑雄 2021-05-18 — — CN disclosed
US-10336775-B2 Glycosidase inhibitors ASCENEURON SA (CH) 2019-07-02 — — US disclosed
US-20170298082-A1 GLYCOSIDASE INHIBITORS ASCENEURON SA (CH) 2017-10-19 — — US disclosed
EP-1899335-A1 PYRROLOQUINOLINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS PIERRE FABRE MEDICAMENT (FR) 2008-03-19 — — EP disclosed
WO-2007111904-A2 C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-04 — — WO disclosed
WO-2007064553-A2 THIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS MERCK & CO., INC. (US) 2007-06-07 — — WO disclosed
US-20070054939-A1 Thiazolypiperidine derivatives as mtp inhibitors MERCK PATNET GMBH (DE) 2007-03-08 — — US disclosed
CN-1918169-A Cysteine protease inhibitors MEDIVIR AB (SE) 2007-02-21 — — CN disclosed
WO-2007003611-A1 PYRROLOQUINOLINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS PIERRE FABRE MEDICAMENT (FR) 2007-01-11 — — WO disclosed
EP-1711180-A1 THIAZOLYLIMIDAZOLE DERIVATIVES AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN MERCK PATENT GmbH (DE) 2006-10-18 — — EP disclosed
EP-1636218-A1 THIAZOLYLPIPERIDINE DERIVATIVES AS MTP INHIBITORS MERCK PATENT GmbH (DE) 2006-03-22 — — EP disclosed
WO-2005074934-A1 THIAZOLYLIMIDAZOLE DERIVATIVES AND THEIR USE AS INHIBITORS OF MICROSMAL TRIGLYCE RIDE TRANSFER PROTEIN MERCK PATENT GMBH (DE) 2005-08-18 — — WO disclosed
WO-2005003128-A1 THIAZOLYLPIPERIDINE DERIVATIVES AS MTP INHIBITORS MERCK PATENT GMBH (DE) 2005-01-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220411440-A1 GLYCOSIDASE INHIBITORS GAA, ENGASE, GBA3 CA12 498/4885CA1 272/4885CA2 1487/4885
US-20170298082-A1 GLYCOSIDASE INHIBITORS GAA, ENGASE, GBA3 CA12 498/4885CA1 272/4885CA2 1487/4885
US-10336775-B2 Glycosidase inhibitors GAA, ENGASE, GBA3 CA12 498/4885CA1 272/4885CA2 1487/4885
US-20070054939-A1 Thiazolypiperidine derivatives as mtp inhibitors MTTP, CETP, APOB CA12 4863/4885CA1 4825/4885CA2 3594/4885
US-11046712-B2 Glycosidase inhibitors GAA, ENGASE, GBA3 CA12 498/4885CA1 272/4885CA2 1487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.